Opioid withdrawal resident survival guide: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) |
||
Line 3: | Line 3: | ||
==Definition== | ==Definition== | ||
[[ | [[Opioid]] withdrawal refers to the arrays of signs and symptoms following the abrupt cessation of [[opioid]]s among chronic users.<br> | ||
Shown below is a table indicative of time to withdrawal symptoms for different opioids:<ref name="Jasinski-1978">{{Cite journal | last1 = Jasinski | first1 = DR. | last2 = Pevnick | first2 = JS. | last3 = Griffith | first3 = JD. | title = Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. | journal = Arch Gen Psychiatry | volume = 35 | issue = 4 | pages = 501-16 | month = Apr | year = 1978 | doi = | PMID = 215096 }}</ref><ref name="Kleber HD."> Opiods: detoxification. In: Galanter M, Kleber HD, eds. The American Psychiatric Press textbook of substance abuse treatment. 2nd ed. Washington, D.C.: American Psychiatric Press, 1999:251-69.></ref> | Shown below is a table indicative of time to withdrawal symptoms for different opioids:<ref name="Jasinski-1978">{{Cite journal | last1 = Jasinski | first1 = DR. | last2 = Pevnick | first2 = JS. | last3 = Griffith | first3 = JD. | title = Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. | journal = Arch Gen Psychiatry | volume = 35 | issue = 4 | pages = 501-16 | month = Apr | year = 1978 | doi = | PMID = 215096 }}</ref><ref name="Kleber HD."> Opiods: detoxification. In: Galanter M, Kleber HD, eds. The American Psychiatric Press textbook of substance abuse treatment. 2nd ed. Washington, D.C.: American Psychiatric Press, 1999:251-69.></ref> | ||
{| Class="wikitable" | {| Class="wikitable" | ||
! Opioid | ! Opioid | ||
! Peak withdrawal symptoms | ! Peak withdrawal symptoms | ||
! Duration of symptoms | ! Duration of symptoms | ||
|- | |- | ||
| [[Heroin]] | | [[Heroin]] | ||
| 36-72 hours | | 36-72 hours | ||
| 7-10 days | | 7-10 days | ||
|- | |- | ||
| [[Methadone]] | | [[Methadone]] | ||
| 72-96 hours | | 72-96 hours | ||
| 14 days or more | | 14 days or more | ||
|- | |- | ||
| [[Buprenorphine]] | | [[Buprenorphine]] | ||
| 36-72 hours | | 36-72 hours | ||
| Intermediate between 7-14 days | | Intermediate between 7-14 days | ||
|- | |- | ||
|} | |} | ||
Revision as of 16:04, 31 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vidit Bhargava, M.B.B.S [2]; Vendhan Ramanujam M.B.B.S [3]
Definition
Opioid withdrawal refers to the arrays of signs and symptoms following the abrupt cessation of opioids among chronic users.
Shown below is a table indicative of time to withdrawal symptoms for different opioids:[1][2]
Opioid | Peak withdrawal symptoms | Duration of symptoms |
---|---|---|
Heroin | 36-72 hours | 7-10 days |
Methadone | 72-96 hours | 14 days or more |
Buprenorphine | 36-72 hours | Intermediate between 7-14 days |
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Opioid withdrawal is a life-threatening condition and must be treated as such irrespective of the causes.
Common Causes
- Discontinuation of heroin
- Discontinuation of methadone
- Rapid detoxification with naloxone or naltrexone in opioid dependent subjects
- Use of partial agonists (buprenorphine) and/or agonist-antagonists (pentazocine) in subjects not known to be opioid dependent
Management
Shown below is an algorithm depicting the management of opioid withdrawal based on hospital concepts.[3]
Characterize the symptoms: ❑ Flu like illness ❑ Lacrimation ❑ Rhinorrhea ❑ Sneezing ❑ Yawning ❑ Anorexia ❑ Nausea ❑ Vomiting ❑ Abdominal cramps ❑ Diarrhea ❑ Myalgia ❑ Arthralgia | |||||||||||||||||||||||||||||||||||||||
Examine the patient: ❑ Increase or unchanged BP ❑ Increase or unchanged HR ❑ Increase or unchanged RR ❑ Mydriasis ❑ Piloerection ❑ Tremor ❑ Increased bowel sounds | |||||||||||||||||||||||||||||||||||||||
Consider alternative diagnosis: ❑ Alcohol withdrawal ❑ Sedative hypnotic withdrawal ❑ Cholinergic poisoning ❑ Sympathomimetic intoxication | |||||||||||||||||||||||||||||||||||||||
Admit the patient | |||||||||||||||||||||||||||||||||||||||
Start opioid agonists:[3] ❑ Methadone (pure agonist) 20-35 mg daily or Add nonopioid drugs: ❑ General symptomatic management ❑ Consult psychiatry | |||||||||||||||||||||||||||||||||||||||
Detoxification[3] | |||||||||||||||||||||||||||||||||||||||
Rapid detoxification:[7] For a patient receiving about 8 mg of buprenorphine or 35 mg of methadone ❑ Detoxify while awake or under mild sedation ❑ Add naltrexone
❑ Add clonidine 0.1-0.2 mg four times daily, tapered on days 2 and 3 ❑ Analgesics as needed | |||||||||||||||||||||||||||||||||||||||
BD: Twice daily; BP: Blood pressure; HR: Heart rate; RR: Respiratory rate
Do's
- Restrict methadone and other opioid agonists to inpatient settings or licensed programs.
- Administer chlordiazepoxide, a longer-acting benzodiazepine to augument clonidine in patients with insomnia or muscle cramps.[5]
- Detoxification should be undertaken only under clinicians with special training, equipment, or both.
- Start buprenorphine at least two days before starting naltrexone during detoxification.
Dont's
- Do not abruptly stop drugs that are being used to treat withdrawal.
References
- ↑ Jasinski, DR.; Pevnick, JS.; Griffith, JD. (1978). "Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction". Arch Gen Psychiatry. 35 (4): 501–16. PMID 215096. Unknown parameter
|month=
ignored (help) - ↑ Opiods: detoxification. In: Galanter M, Kleber HD, eds. The American Psychiatric Press textbook of substance abuse treatment. 2nd ed. Washington, D.C.: American Psychiatric Press, 1999:251-69.>
- ↑ 3.0 3.1 3.2 Huitink, J.; Buitelaar, D. (2003). "Management of drug and alcohol withdrawal". N Engl J Med. 349 (4): 405–7, author reply 405-7. PMID 12879900. Unknown parameter
|month=
ignored (help) - ↑ Senay, EC.; Dorus, W.; Goldberg, F.; Thornton, W. (1977). "Withdrawal from methadone maintenance. Rate of withdrawal and expectation". Arch Gen Psychiatry. 34 (3): 361–7. PMID 843188. Unknown parameter
|month=
ignored (help) - ↑ 5.0 5.1 O'Connor, PG.; Waugh, ME.; Carroll, KM.; Rounsaville, BJ.; Diagkogiannis, IA.; Schottenfeld, RS. (1995). "Primary care-based ambulatory opioid detoxification: the results of a clinical trial". J Gen Intern Med. 10 (5): 255–60. PMID 7616334. Unknown parameter
|month=
ignored (help) - ↑ Strang, J.; Bearn, J.; Gossop, M. (1999). "Lofexidine for opiate detoxification: review of recent randomised and open controlled trials". Am J Addict. 8 (4): 337–48. PMID 10598217.
- ↑ O'Connor, PG.; Carroll, KM.; Shi, JM.; Schottenfeld, RS.; Kosten, TR.; Rounsaville, BJ. (1997). "Three methods of opioid detoxification in a primary care setting. A randomized trial". Ann Intern Med. 127 (7): 526–30. PMID 9313020. Unknown parameter
|month=
ignored (help) - ↑ Presslich, O.; Loimer, N.; Lenz, K.; Schmid, R. (1989). "Opiate detoxification under general anesthesia by large doses of naloxone". J Toxicol Clin Toxicol. 27 (4–5): 263–70. PMID 2600989.
- ↑ Loimer, N.; Lenz, K.; Schmid, R.; Presslich, O. (1991). "Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates". Am J Psychiatry. 148 (7): 933–5. PMID 2053636. Unknown parameter
|month=
ignored (help)